Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185481 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03185481: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT03185481 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185481, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE).
Interventions
- DRUG 1 mg QD to 15 mg QD PF-06649751
- DRUG 3 mg QD to 15 mg QD PF-06649751
- DRUG 7 mg QD to 15 mg QD PF-06649751
- DRUG 15 mg QD PF-06649751
- DRUG 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 2 |
Why NCT03185481 stopped before completion
NCT03185481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which 1 mg QD to 15 mg QD PF-06649751 is the first listed.
NCT03185481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185481 about?
NCT03185481 is a clinical study titled "Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations". The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
What is the current status of trial NCT03185481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-07-06. Estimated completion is 2017-10-25.
What interventions are being tested in trial NCT03185481?
The interventions under investigation include: 1 mg QD to 15 mg QD PF-06649751 (DRUG), 3 mg QD to 15 mg QD PF-06649751 (DRUG), 7 mg QD to 15 mg QD PF-06649751 (DRUG), 15 mg QD PF-06649751 (DRUG), 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) (DRUG).
Who is sponsoring clinical trial NCT03185481?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03185481's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI